Temozolomide plus radiotherapy improves survival in non-co-deleted glioma

Patients with newly diagnosed non-co-deleted anaplastic glioma may experience greater survival outcomes with adjuvant temozolomide compared with radiotherapy only, according to results from a phase 3, randomised, open-label study published in the Lancet.
Neurology Advisor